DBI Mouse
Acyl-CoA-binding protein, ACBP, Diazepam-binding inhibitor, DBI, Endozepine, EP, Dbi.
Greater than 95.0% as determined by SDS-PAGE.
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Description
DBI Mouse Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 110 amino acids (1-87 a.a) and having a molecular mass of 12.4kDa. DBI is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Acyl-CoA-binding protein, ACBP, Diazepam-binding inhibitor, DBI, Endozepine, EP, Dbi.
MGSSHHHHHH SSGLVPRGSH MGSMSQAEFD KAAEEVKRLK TQPTDEEMLF IYSHFKQATV GDVNTDRPGL LDLKGKAKWD SWNKLKGTSK ESAMKTYVEK VDELKKKYGI
Product Science Overview
DBI was first identified due to its ability to displace diazepam from its binding sites on the gamma-aminobutyric acid (GABA) type A receptors in the brain. This discovery led to its name, Diazepam Binding Inhibitor. However, it is also known as Acyl-Coenzyme A Binding Protein (ACBP) due to its role in binding acyl-CoA esters within cells .
DBI/ACBP is a small protein consisting of approximately 86 amino acids. It has a high affinity for medium- and long-chain acyl-CoA esters, which are crucial intermediates in lipid metabolism. The protein’s structure allows it to interact with various cellular components, influencing metabolic pathways and signal transduction processes .
-
Intracellular Functions:
- Lipid Metabolism: DBI/ACBP binds to acyl-CoA esters, facilitating their transport and utilization in metabolic pathways. This function is essential for maintaining cellular lipid homeostasis .
- Signal Transduction: Within cells, DBI/ACBP can modulate signal transduction pathways by interacting with specific receptors and enzymes .
-
Extracellular Functions:
- Neurotransmission: DBI acts as a neuropeptide in the brain, modulating the activity of GABA type A receptors. This interaction influences various neurological processes, including anxiety, sleep, and seizure susceptibility .
- Appetite Regulation: Recent studies have shown that DBI/ACBP can influence appetite and energy balance. Elevated levels of DBI/ACBP are associated with increased food intake and obesity, while its neutralization can reduce food intake and promote weight loss .
Recombinant DBI (Mouse) is produced using genetic engineering techniques to study its functions and potential therapeutic applications. By expressing the mouse DBI gene in bacterial or mammalian cell systems, researchers can obtain large quantities of the protein for experimental purposes. This recombinant protein is used to investigate DBI’s role in various physiological and pathological conditions, including metabolic disorders, psychiatric diseases, and pain modulation .
The multifunctional nature of DBI/ACBP makes it a potential target for therapeutic interventions. For instance:
- Metabolic Disorders: Modulating DBI/ACBP activity could provide new strategies for treating obesity and related metabolic conditions .
- Neurological Disorders: Given its role in GABAergic neurotransmission, DBI could be a target for developing treatments for anxiety, epilepsy, and other neurological disorders .
- Pain Management: DBI’s involvement in pain signaling pathways suggests it could be a target for novel pain therapies .
